Plasma genomic testing for advanced non-small cell lung cancer
PLAsma Genomic Testing in Patients With Advanced Non-Small Cell Lung Cancer: The PLAN Study
This study is testing if a blood test for genetic changes can help doctors find better treatments for people newly diagnosed with advanced non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 97 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal College of Surgeons, Ireland Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, osimertinib, gefitinib, erlotinib, crizotinib, alectinib, ceritinib |
| Locations | 3 sites (Dublin and 2 other locations) |
| Trial ID | NCT05542485 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of plasma genotyping for initial genomic testing in patients newly diagnosed with advanced or locally advanced non-squamous non-small cell lung cancer (NSCLC). Patients will undergo a plasma genotyping assay alongside standard tissue-based biopsy and genotyping at Rapid Access Lung Cancer Clinics. The study aims to identify actionable genomic alterations that can guide targeted therapies, improving treatment outcomes for this diverse cancer type.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a radiological suspicion of advanced or locally advanced non-squamous NSCLC who have not received prior systemic therapy.
Not a fit: Patients with squamous cell subtype NSCLC or those who have previously received systemic anti-cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the precision of treatment options for patients with advanced non-small cell lung cancer by identifying actionable mutations earlier.
How similar studies have performed: Other studies have shown success with similar genomic testing approaches, indicating a promising avenue for improving treatment strategies in lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Radiological suspicion of advanced or locally advanced non-small cell lung cancer 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 4. Ability of subject to understand and the willingness to sign a written informed consent document. Second arm additional criteria 5. Planned for systemic treatment with either single agent immunotherapy (IT) or combination chemotherapy/IT 6. No prior systemic therapy for advanced NSCLC Exclusion Criteria: 1. Squamous cell subtype NSCLC histology 2. Small cell carcinoma histology 3. Patients who have received systemic anti-cancer treatment
Where this trial is running
Dublin and 2 other locations
- Beaumont Hospital — Dublin, Ireland (Recruiting)
- St. James' Hospital — Dublin, Ireland (Recruiting)
- University Hospital Limerick — Limerick, Ireland (Recruiting)
Study contacts
- Study coordinator: Jarushka Naidoo, MB MBS
- Email: davidoreilly22@rcsi.ie
- Phone: 018092082
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.